Controlled-release hydrophilic tablets for individualized theophylline therapy

Drug Development and Industrial Pharmacy

Volumn 25, Issue 2, 1999, Pages 187-196

  Sabnis, Shobhan ^a,b   Adeyeye, Christianah Moji ^a  

^a DUQUESNE UNIVERSITY   (United States)

^b ZOETIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLCELLULOSE; THEOPHYLLINE;

ARTICLE; COMPUTER PROGRAM; CONTROLLED DRUG RELEASE; DRUG CLEARANCE; DRUG DISTRIBUTION; HUMAN; HYDROPHILICITY; MAJOR CLINICAL STUDY; TABLET FORMULATION; VISCOSITY;

COMPUTER SIMULATION; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; TABLETS; THEOPHYLLINE; VASODILATOR AGENTS;

EID: 0032968130     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-100102159     Document Type: Article

References (26)

1. W. J. Jusko, M. J. Gardner, A. Mangione, J. J. Schentag, J. R. Koup, and J. Vance, J. Pharm. Sci., 68, 1358-1366 (1979).
2. J. R. Koup, C. M. Sack, A. Smith, and M. Gibaldi, Clin. Pharmacokinet., 4, 460-469 (1979).
3. L. Hendeles, P. Iafrate, and M. Weinberger, Clin. Pharmacokinet., 9, 95-135 (1984).
4. K. J. Simons, F. E. R. Simons, K. D. Plett, and C. Scerbo, J. Pharm. Sci., 73, 939-942 (1984).
5. D. L. Spangler, D. D. Kalof, F. L. Bloom, and H. J. Wittig, Ann. Allergy, 40, 6-11 (1978).
6. S. M. Erdman, K. A. Rodvold, and R. D. Pryka, Clin. Pharmacokinet., 20, 280-292 (1991).
7. B. Lacarelle, P. Pisano, T. Gauthier, P. H. Villard, F. Guder, J. Catalin, and A. Durand, Int. J. Biomed. Comput., 36, 127-130 (1994).
8. G. E. Stein, D. B. Haughey, R. J. Ross, and J. Vakoutis, Drug Intel. Clin. Pharm., 16, 772-774 (1982).
9. U.S. Pharmacopeial Convention, The United States Pharmacopeia 23/National Formulary 18, Author, Rockville, MD, 1995, pp. 774-775.
10. D. Train, J. Pharm. Pharmacol., 10, 127T (1958).
11. J. R. Roup, J. Schentag, J. Vance, P. M. Kuritzky, D. Pyszczynski, and W. J. Jusko, Am. J. Hosp. Pharm., 33, 949-956 (1976).
12. U. Finne and A. Urtti, Int. J. Pharm., 84, 217-222 (1992).
13. M. W. Ramsey, G. M. Grass, and J. J. Vallner, Eur. J. Pharm. Biopharm., 37, 192-197 (1991).
14. W. L. Haydon and P. L. Collins, Am. J. Pharm. Ed., 55, 131-134 (1991).
15. D. K. Bogen, Science, 246, 138-142 (October 6, 1989).
16. M. L. Slotfeldt, C. E. Johnson, G. Grambau, and J. G. Weg, Am. J. Hosp. Pharm., 36, 66-68 (1979).
17. K. Diem and C. Lentner (eds.), Scientific Tables, 7th ed., Ciba-Geigy, Basle, Switzerland, 1971, p. 711.
18. J. I. Wells, in Pharmaceutical Preformulation, Ellis Horwood, W. Sussex, UK, 1988, pp. 209-214.
19. R. E. Gordon, T. W. Rosanske, D. E. Fonner, N. R. Anderson, and G. S. Banker, in Pharmaceutical Dosage Forms: Tablets, Vol. 2 (H. A. Liebermann, L. Lachman, and J. B. Schwartz, eds.), Marcel Dekker, New York, 1990, pp. 245-348.
20. C. M. Adeyeye, J. Rowley, D. Madu, M. Javadi, and S. S. Sabnis, Int. J. Pharm., 116, 65-75 (1995).
21. A. Stamm and J. Tritsch, in Pharmaceutical Technology: Controlled Drug Release, Vol. 1 (M. Rubinstein, ed.), Ellis Horwood, W. Sussex, UK, 1987, pp. 55-63.
22. Dow Chemical Company, Formulating for Controlled Release with Methocel Premium Cellulose Ethers, Author, Midland, MI, 1995.
23. L. C. Laursen, N. Johannesson, and B. Weeke, Eur. J. Clin. Pharmacol., 29, 115-117 (1985).
24. M. Weinberger, L. Hendeles, L. Wong, and L. Vaughan, J. Pediatr., 99, 145-152 (1981).
25. E. Sarrazin, L. Hendeles, M. Wein, K. Muir, and S. Riegelman, J. Pediatr., 97, 825-828 (1980).
26. R. J. Rackley, M. C. Meyer, and A. B. Straughn, J. Pharm. Sci., 77, 658-661 (1988).